Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain
CompletedNot applicableNCT05311774
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Cancer pain is one of the most common and problematic symptoms. Opioids are typically the most common drugs used in the treatment of cancer pain,they are limited due to their side effects. Tramadol is a centrally acting non-opiate analgesic with low affinity for μ-opioid receptors, and is effective in the treatment of moderate to severe pain. Neuropathic pain is typically not amenable to standard opiate therapy, and the addition of tricyclic antidepressants or/and antiepileptic drugs can offer a very effective treatment strategy in such patients. Duloxetine is a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) that has been used traditionally for its antidepressant qualities and has also analgesic benefit in the treatment of neuropathic pain. Duloxetine exerts its analgesic action through central and peripheral pain modulation .
Study details
- Official title
- Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain
- Conditions
- Interventions
- Drug: Duloxetine 30 mg
- Drug: Tramadol
- Drug: Placebo
- Sponsor
- Assiut University
- Start date
- 2022-04-01
- Primary completion
- 2025-10-01
- Sex
- All
- Age range
- from 20 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with cancer pain 1. age from 20-70 years old. 2. not receiving any type of analgesia before (opioid naïve, no adjuvants). Exclusion Criteria: 1. Difficult to be assessed for pain. 2. Any contraindication for duloxetine or tramadol.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05311774